{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:34:13Z","timestamp":1793255653443,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Zoledronate prevented fractures in 4 large trials in cohorts that varied from low to high risk of fracture. Cost-effectiveness analyses are important tools used in funding and regulatory decisions about pharmaceutical agents, and zoledronate generally has appeared to be cost-effective. We used a simple approach to compare zoledronate costs with the savings from fractures prevented to complement previous cost-effectiveness analyses. Eighteen month costs of major osteoporotic fractures were obtained from published data from 7 US sites in the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) study, costs of zoledronate medication from Medicare, and infusion costs estimated empirically. We applied these costs to data on major osteoporotic fracture from the 4 trials. We repeated these analyses using 12-mo costs from 11 international ICUROS sites. In the trials with high-risk and intermediate-high risk cohorts, the cost-savings from major osteoporotic fractures prevented were approximately US $500\u2009000\/1000 patients\/3\u00a0yr. In the low-intermediate-risk trial, they were $660\u2009000\/1000\/6\u00a0yr, and in the low-risk trial, $240\u2009000\/1000\/10\u00a0yr. When the international fracture cost data were used, these savings approximately doubled. In all 4 trials, the total costs of zoledronate were substantially less than the savings from fractures prevented, with annual savings ranging from $11 to $88\/patient\/yr in low-risk to high-risk patients. The cost-neutral zoledronate cost (maximum infusion cost plus medication cost) ranged from $160 to $175 using the US fracture cost data, and was about $350 using international cost data. In summary, in 4 trials with cohorts at various risk of fracture ranging from low to high risk, zoledronate produced substantial net savings because the costs of fractures prevented out-weighed total zoledronate costs.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag066","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:41:59Z","timestamp":1775907719000},"page":"1195-1201","source":"Crossref","is-referenced-by-count":1,"title":["Cost-savings from fracture prevention with zoledronate in randomized controlled trials"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-2674","authenticated-orcid":false,"given":"Mark J","family":"Bolland","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland 1142 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-0096","authenticated-orcid":false,"given":"Andrew","family":"Grey","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland 1142 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland , Auckland 1142 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"2026102901462118800_ref1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","article-title":"Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the us branch of the international osteoporosis foundation","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos Int"},{"issue":"2","key":"2026102901462118800_ref2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","article-title":"An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis","volume":"39","author":"Li","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"2026102901462118800_ref3","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00198-025-07621-y","article-title":"A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women","volume":"36","author":"Cassinat","year":"2025","journal-title":"Osteoporos Int"},{"issue":"7","key":"2026102901462118800_ref4","doi-asserted-by":"publisher","first-page":"ziaf077","DOI":"10.1093\/jbmrpl\/ziaf077","article-title":"Longitudinal patient outcomes over 18 months following a hip, clinical vertebral, distal forearm, or proximal humerus fracture in the United States: results from the ICUROS us study","volume":"9","author":"Silverman","year":"2025","journal-title":"JBMR Plus"},{"issue":"9","key":"2026102901462118800_ref5","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00198-022-06460-5","article-title":"A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)","volume":"33","author":"Talevski","year":"2022","journal-title":"Osteoporos Int"},{"issue":"18","key":"2026102901462118800_ref6","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2026102901462118800_ref7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2026102901462118800_ref8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2026102901462118800_ref9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026102901462118800_ref10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate - results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"issue":"36","key":"2026102901462118800_ref11","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1503\/cmaj.161207","article-title":"Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial","volume":"189","author":"Grey","year":"2017","journal-title":"CMAJ"},{"issue":"4","key":"2026102901462118800_ref12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026102901462118800_ref13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3111\/13696998.2010.545563","article-title":"The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands","volume":"14","author":"Akehurst","year":"2011","journal-title":"J Med Econ"},{"issue":"78","key":"2026102901462118800_ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"issue":"11","key":"2026102901462118800_ref15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","article-title":"Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a nice single technology appraisal","volume":"29","author":"Scotland","year":"2011","journal-title":"Pharmacoeconomics"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag066\/68032677\/zjag066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1195\/68032677\/zjag066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1195\/68032677\/zjag066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:46:29Z","timestamp":1793252789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/11\/1195\/8651576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,4,11]]},"published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag066","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,4,11]]}}}